What is it about?
Direct hemoperfusion using the CYT-860, a cytokine-adsorber column (CYT-860-DHP), was performed in critically ill patients with hypercytokinemia. To evaluate the efficacy of CYT-860-DHP, changes in pathological and clinical parameters were examined. Seven patients with hypercytokinemia and a SOFA score of ≧5 underwent CYT-860-DHP treatment. Four patients survived 28 days after CYT-860-DHP treatment. Significant decreases in blood levels of cytokines were observed. PaO2/FIO2 improved significantly.
Featured Image
Why is it important?
The possibility that CYT-860-DHP treatment can reduce blood cytokine levels and thereby improve the general condition of patients was suggested.
Perspectives
These findings warrant the initiation of a prospective randomized trial to evaluate the clinical efficacy of CYT-860-DHP treatment.
Dr Yoshiro Kobe
Chiba Emergency Medical Center
Read the Original
This page is a summary of: Direct Hemoperfusion with a Cytokine-Adsorbing Device for the Treatment of Persistent or Severe Hypercytokinemia: A Pilot Study, Blood Purification, January 2007, Karger Publishers,
DOI: 10.1159/000111568.
You can read the full text:
Contributors
The following have contributed to this page
